WO2010055133A1 - Dérivés de benzimidazole et leur utilisation dans la modulation du complexe du récepteur gabaa - Google Patents

Dérivés de benzimidazole et leur utilisation dans la modulation du complexe du récepteur gabaa Download PDF

Info

Publication number
WO2010055133A1
WO2010055133A1 PCT/EP2009/065126 EP2009065126W WO2010055133A1 WO 2010055133 A1 WO2010055133 A1 WO 2010055133A1 EP 2009065126 W EP2009065126 W EP 2009065126W WO 2010055133 A1 WO2010055133 A1 WO 2010055133A1
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
pain
stereoisomers
disease
pharmaceutically acceptable
Prior art date
Application number
PCT/EP2009/065126
Other languages
English (en)
Inventor
Janus S. Larsen
Philip K. Ahring
Elsebet Østergaard NIELSEN
Naheed Mirza
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Publication of WO2010055133A1 publication Critical patent/WO2010055133A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • TECHNICAL FIELD This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith.
  • the compounds of the invention are useful in the treatment of central nervous system diseases and disorders which are responsive to modulation of the GABA A receptor complex, and in particular for combating anxiety and related diseases.
  • the modulatory sites on the GABA A receptor complex are the target for anxiolytic drugs, such as the classical anxiolytic benzodiazepines. However, they are associated with a number of undesirable features.
  • each receptor is a pentameric complex comprising subunits drawn from ⁇ i -6 , ⁇ i-3, ⁇ i-3, ⁇ , ⁇ , and ⁇ subunit isoforms.
  • the classical anxiolytic benzodiazepines show no subtype selectivity. It has been suggested that one of the key elements in the disadvantages of the classical benzodiazepanes (such as sedation, dependency, and cognitive impairment) is relates to the ⁇ 1 subunit of the GABA A receptors.
  • compounds with selectivity for the cc2 and/or cc3 subunits over the ⁇ 1 subunit are expected to have an improved side effect profile.
  • the invention provides a compound of Formula I:
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of the invention, or an N-oxide thereof, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention provides the use of a compound of the invention, or an N-oxide thereof, any of its stereoisomers or any mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the GABA A receptor complex.
  • the invention relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of the GABA A receptor complex, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention, or an N-oxide thereof, any of its stereoisomers or any mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof.
  • R represents a phenyl group; which phenyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, thfluoromethyl, thfluoromethoxy, cyano, nitro, alkyl, hydroxy, hydroxyalkyl and alkoxy.
  • R represents a phenyl group, which phenyl group is substituted with one or more substituents independently selected from the group consisting of: halo and cyano.
  • R represents
  • R 1 and R 2 independent of each other represent hydrogen, halo, thfluoromethyl, thfluoromethoxy, cyano, nitro, alkyl, hydroxy, hydroxyalkyl or alkoxy.
  • R 1 represents cyano.
  • R 2 represents hydrogen.
  • R 2 represents halo, such as chloro.
  • R represents 2-cyano-phenyl or 3-chloro-2-cyano-phenyl.
  • the compound of the invention is 2- ⁇ 4-[5-(1 -Hydroxy-1 -methyl-ethyl)-benzoimidazol-1 -yl]-pyridin-2-yl ⁇ -benzonitrile; 2-Chloro-6- ⁇ 4-[5-(1 -hydroxy-1 -methyl-ethyl)-benzoimidazol-1 -yl]-pyridin-2-yl ⁇ - benzonithle; or an N-oxide thereof, any of its stereoisomers or any mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof.
  • alkyl as used herein means a saturated, branched or straight hydrocarbon group having from 1 -6 carbon atoms, e.g. Ci -3 -alkyl, Ci -4 -alkyl, Ci -6 - alkyl, C2-6-alkyl, C3-6-alkyl, and the like. Representative examples are methyl, ethyl, propyl (e.g. prop-1 -yl, prop-2-yl (or /so-propyl)), butyl (e.g. 2-methylprop-2- yl (or te/t-butyl), but-1-yl, but-2-yl), pentyl (e.g.
  • pent-1-yl pent-2-yl, pent-3-yl
  • 2- methylbut-1 -yl 3-methylbut-1 -yl
  • hexyl e.g. hex-1 -yl
  • heptyl e.g. hept-1 -yl
  • octyl e.g. oct-1-yl
  • nonyl e.g. non-1 -yl
  • halo or halogen means fluorine, chlorine, bromine or iodine.
  • cyano shall mean the radical -CN.
  • nitro shall mean the radical -NO2.
  • hydroxy shall mean the radical -OH.
  • hydroxyalkyl refers to Ci- 6 -alkyl substituted one or more times at any carbon atom(s) with hydroxyl.
  • Representative examples are hydroxymethyl, hydoxyethyl (e.g. 1-hydroxyethyl, 2-hydroxyethyl) and the like.
  • alkoxy refers to the radical -O-Ci-6-alkyl. Representative examples are methoxy, ethoxy, propoxy (e.g. 1 -propoxy, 2- propoxy), butoxy (e.g. 1 -butoxy, 2-butoxy, 2-methyl-2-propoxy), pentoxy (1 - pentoxy, 2-pentoxy), hexoxy (1 -hexoxy, 3-hexoxy), and the like.
  • optionally substituted as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the group(s) in question is/are substituted with more than one substituent the substituents may be the same or different.
  • treatment means the management and care of a patient for the purpose of combating a disease, disorder or condition.
  • the term is intended to include the delaying of the progression of the disease, disorder or condition, the alleviation or relief of symptoms and complications, and/or the cure or elimination of the disease, disorder or condition.
  • the patient to be treated is preferably a mammal, in particular a human being.
  • medicament means a pharmaceutical composition suitable for administration of the pharmaceutically active compound to a patient.
  • pharmaceutically acceptable means suited for normal pharmaceutical applications, i.e. giving rise to no adverse events in patients etc.
  • effective amount means a dosage which is sufficient in order for the treatment of the patient to be effective compared with no treatment.
  • terapéuticaally effective amount of a compound as used herein means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications. An amount adequate to accomplish this is defined as “therapeutically effective amount”. Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician or veterinary.
  • the compounds of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the compounds of the invention.
  • Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the sulphate derived from sulphuric acid, the formate derived from formic acid, the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulphonate derived from benzensulphonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the fumarate derived from fuma
  • acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a compound of the invention and its pharmaceutically acceptable acid addition salt.
  • Examples of pharmaceutically acceptable cationic salts of a compound of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysinium, and the ammonium salt, and the like, of a compound of the invention containing an anionic group.
  • Such cationic salts may be formed by procedures well known and described in the art.
  • onium salts of N-containing compounds are also contemplated as pharmaceutically acceptable salts.
  • Preferred “onium salts” include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.
  • pre- or prodrug forms of the compound of the invention include examples of suitable prodrugs of the substances according to the invention including compounds modified at one or more reactive or derivatizable groups of the parent compound. Of particular interest are compounds modified at a carboxyl group, a hydroxyl group, or an amino group. Examples of suitable derivatives are esters or amides.
  • the compound of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like.
  • Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
  • the invention includes all such stereoisomers and any mixtures thereof in- eluding racemic mixtures.
  • Optical active compounds can also be prepared from optical active starting materials.
  • an N-oxide designates an oxide derivative of a tertiary amine, including a nitrogen atom of an aromatic N-heterocyclic compound, a non-aromatic N-heterocyclic compounds, a thalkylamine and a thalkenylamine.
  • the N-oxide of a compound containing a pyridyl may be the 1 -oxy-pyridin- 2, -3 or -4-yl derivative.
  • N-oxides of the compounds of the invention may be prepared by oxidation of the corresponding nitrogen base using a conventional oxidizing agent such as hydrogen peroxide in the presence of an acid such as acetic acid at an elevated temperature, or by reaction with a peracid such as peracetic acid in a suitable solvent, e.g. dichloromethane, ethyl acetate or methyl acetate, or in chloroform or dichloromethane with 3-chloroperoxybenzoic acid.
  • a suitable solvent e.g. dichloromethane, ethyl acetate or methyl acetate, or in chloroform or dichloromethane with 3-chloroperoxybenzoic acid.
  • the compounds of the invention may be used in their labelled or unlabelled form.
  • the labelled compound has one or more atoms replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • the labelling will allow easy quantitative detection of said compound.
  • the labelled compounds of the invention may be useful as diagnostic tools, radio tracers, or monitoring agents in various diagnostic methods, and for in vivo receptor imaging.
  • the labelled isomer of the invention preferably contains at least one radionuclide as a label. Positron emitting radionuclides are all candidates for usage. In the context of this invention the radionuclide is preferably selected from
  • the physical method for detecting the labelled isomer of the present invention may be selected from Position Emission Tomography (PET), Single
  • the compounds of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples.
  • the starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • one compound of the invention can be converted to another compound of the invention using conventional methods.
  • the end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
  • the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
  • pharmaceutically acceptable solvents such as water, ethanol and the like.
  • the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
  • Compounds of the invention are capable of modulating the GABA A receptor complex. They may be tested for their ability to bind to the GABA A receptor complex, including specific subunits thereof.
  • the compounds of the present invention being ligands for the benzodiazepine binding site on GABA A receptors, are therefore of use in the treatment and/or prevention of a variety of disorders of and outside the central nervous system.
  • the compounds of the invention are considered useful for the treatment, prevention or alleviation of a disease, disorder or condition responsive to modulation of the GABA A receptor complex, in particular in the central nervous system.
  • the compounds of the invention are ligands of the GABA A receptor complex outside the central nervous system.
  • the compounds of the invention are considered useful for the treatment, prevention or alleviation of anxiety disorders, panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, phobia, animal phobia, social phobia, obsessive-compulsive disorder (OCD), generalized anxiety disorder, substance-induced anxiety disorder; stress disorders, posttraumatic stress disorder, separation anxiety disorder, acute stress disorder, sleep disorder, memory disorder, neurosis, convulsive disorder, epilepsy, seizures, convulsions, febrile convulsions in children, mood disorder, depressive disorder, bipolar disorder, depression, major depressive disorder, single-episode major depressive disorder, recurrent major depressive disorder, dysthymic disorder, bipolar disorder, manic disorder, bipolar I manic disorder, bipolar Il manic disorder, cyclothymic disorder, psychotic disorder, schizophrenia, cognitive disorder, learning deficit, memory deficits and dysfunction, dementia, attention deficit, attention deficit hyperactivity disorder (ADHD), Down's syndrome, Tourette's syndrome, Alzheimer's disease
  • the compounds are considered useful for the treatment or alleviation of anxiety, e.g. anxiety disorders, panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, phobia, animal phobia, social phobia, obsessive-compulsive disorder, generalized anxiety disorder, substance-induced anxiety disorder; stress disorders, post-traumatic stress disorder, separation anxiety disorder, acute stress disorder or, sleep disorder.
  • anxiety disorders e.g. anxiety disorders, panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, phobia, animal phobia, social phobia, obsessive-compulsive disorder, generalized anxiety disorder, substance-induced anxiety disorder; stress disorders, post-traumatic stress disorder, separation anxiety disorder, acute stress disorder or, sleep disorder.
  • the compounds are considered useful for the treatment or alleviation of anxiety.
  • the compounds are considered useful for the treatment or alleviation of pain, e.g.
  • the compounds are considered useful for the treatment or alleviation of pain.
  • the compounds are considered useful for the treatment or alleviation of schizophrenia, cognitive disorder, learning deficit, memory deficits and dysfunction, dementia, attention deficit, attention deficit hyperactivity disorder (ADHD), Down's syndrome, Tourette's syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, cognitive impairment, cognition deficits in schizophrenia, tichotillamania, stuttering, general tic disorders, muscle tension disorders, cerebral ischemia, stroke, head trauma, neurodegeneration arising from cerebral ischemia.
  • the compounds are considered useful for the treatment or alleviation of schizophrenia.
  • the compounds of the invention may be useful as radioligands in assays for detecting compounds capable of binding to the human GABA A receptor.
  • a suitable dosage of the active pharmaceutical ingredient (API) is within the range of from about 0.1 to about 1000 mg API per day, more preferred of from about 10 to about 500 mg API per day, most preferred of from about 30 to about 100 mg API per day, dependent, however, upon the exact mode of administration, the form in which it is administered, the indication considered, the subject and in particular the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the compound of the invention.
  • a compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • the invention provides pharmaceutical compositions comprising the compound of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
  • compositions of the invention may be those suitable for oral, rectal, bronchial, nasal, pulmonal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems.
  • sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules.
  • compositions and unit dosages thereof may thus be placed into the form of pharmaceutical compositions and unit dosages thereof.
  • forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • the compound of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, cellulose, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glycehde or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.
  • Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
  • the compound according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • a suitable vehicle e.g. sterile, pyrogen-free water
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • solid form preparations intended for conversion shortly before use to liquid form preparations for oral administration.
  • Such liquid forms include solutions, suspensions, and emulsions.
  • such preparations may comprise colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the compound of the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • compositions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
  • the compositions may be provided in single or multi-dose form.
  • Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, thchlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, thchlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • CFC chlorofluorocarbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by provision of a
  • the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
  • the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micron ization.
  • compositions adapted to give sustained release of the active ingredient may be employed
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the invention provides tablets or capsules for oral administration.
  • the invention provides liquids for intravenous administration and continuous infusion.
  • compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
  • the active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 ⁇ g/kg i.v. and 1 ⁇ g/kg p.o.
  • the upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o.
  • Preferred ranges are from about 0.1 ⁇ g/kg to about 10 mg/kg/day i.v., and from about 1 ⁇ g/kg to about 100 mg/kg/day p.o.
  • the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of the GABA A receptor complex, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a compound of the invention.
  • suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • target compounds 7a-7b 35 (95:5:0.1 %) as mobile phase to give target compounds 7a-7b.
  • the compounds of the present invention may be tested for their in vitro actions, pharmacokinetic properties and in vivo actions using standard pharmacological procedures in cell cultures or experimental animals, such as those de- scribed in Mirza NR et al, NS11394 ([3'-[5-(1 -Hydroxy-1 -methyl-ethyl)- benzoimidazol-1 -yl]-biphenyl-2-carbonithle]), a unique subtype-selective GABA A receptor positive modulator: In vitro actions, pharmacokinetic properties and in- vivo anxiolytic efficacy; Journal of Pharmacology And Experimental Therapeutics Fast Forward; first published on September 12, 2008; DOI: 10.1124/jpet.108.138859. Test method 1
  • the GABA recognition site and the benzodiazepine modulatory unit can selectively be labelled with 3 H-flunitrazepam.
  • Cerebral cortex from male Wistar rats (150-200 g) is homogenised for 5-10 sec in 20 ml Tris-HCI (30 mM, pH 7.4) using an Ultra-Turrax homogeniser. The suspension is centrifuged at 27,000 x g for 15 min and the pellet is washed three times with buffer (centrifuged at 27,000 x g for 10 min). The washed pellet is homogenized in 20 ml of buffer and incubated on a water bath (37°C) for 30 min to remove endogenous GABA and then centrifuged for 10 min at 27,000 x g. The pellet is then homogenized in buffer and centrifuged for 10 min at 27,000 x g. The final pellet is resuspended in 30 ml buffer and the preparation is frozen and stored at - 20 0 C.
  • the membrane preparation is thawed and centrifuged at 2°C for 10 min at 27,000 x g.
  • the pellet is washed twice with 20 ml 50 mM Tris-citrate, pH 7.1 using an Ultra-Turrax homogeniser and centrifuged for 10 min at 27,000 x g.
  • the final pellet is resuspended in 50 mM Tris-citrate, pH 7.1 (500 ml buffer per g of original tissue), and then used for binding assays. Aliquots of 0.5 ml tissue are added to 25 ⁇ l of test solution and 25 ⁇ l Of 3 H-FNM (1 nM, final concentration), mixed and in- cubated for 40 min at 2°C.
  • Non-specific binding is determined using Clonazepam (1 ⁇ M, final concentration). After incubation the samples are added 5 ml of ice-cold buffer and poured directly onto Whatman GF/C glass fibre filters under suction and immediately washed with 5 ml ice-cold buffer. The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.
  • IC 5 O the concentration ( ⁇ M) of the test substance which inhibits the specific binding Of 3 H-FNM by 50%.
  • C 0 is specific binding in control assays
  • C x is the specific binding in the test assay. (The calculations assume normal mass-action kinetics).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de benzimidazole et leur utilisation en tant que modulateurs du complexe du récepteur GABAA. Dans d'autres aspects, l'invention concerne l'utilisation de ces composés dans une méthode thérapeutique, et des compositions pharmaceutiques contenant ces composés.
PCT/EP2009/065126 2008-11-14 2009-11-13 Dérivés de benzimidazole et leur utilisation dans la modulation du complexe du récepteur gabaa WO2010055133A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11494508P 2008-11-14 2008-11-14
US61/114,945 2008-11-14
DKPA200801586 2008-11-14
DKPA200801586 2008-11-14

Publications (1)

Publication Number Publication Date
WO2010055133A1 true WO2010055133A1 (fr) 2010-05-20

Family

ID=41560877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/065126 WO2010055133A1 (fr) 2008-11-14 2009-11-13 Dérivés de benzimidazole et leur utilisation dans la modulation du complexe du récepteur gabaa

Country Status (1)

Country Link
WO (1) WO2010055133A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10624839B2 (en) 2014-03-13 2020-04-21 Neuroderm, Ltd. Dopa decarboxylase inhibitor compositions
US10813902B2 (en) 2014-03-13 2020-10-27 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563001A1 (fr) * 1992-03-26 1993-09-29 Neurosearch A/S Dérivés de l'imidazole, leur préparation et leur utilisation
EP0616807A1 (fr) * 1993-03-24 1994-09-28 Neurosearch A/S Benzimidazoles utiles dans le traitement des affections du système nerveux central
WO2004087690A2 (fr) * 2003-04-03 2004-10-14 Neurosearch A/S Derives de benzimidazole et leur utilisation pour moduler le complexe du recepteur gabaa
WO2007110374A1 (fr) * 2006-03-24 2007-10-04 Neurosearch A/S Dérivés de benzimidazole et utilisation de ceux-ci pour moduler le complexe récepteur gabaa

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563001A1 (fr) * 1992-03-26 1993-09-29 Neurosearch A/S Dérivés de l'imidazole, leur préparation et leur utilisation
EP0616807A1 (fr) * 1993-03-24 1994-09-28 Neurosearch A/S Benzimidazoles utiles dans le traitement des affections du système nerveux central
WO2004087690A2 (fr) * 2003-04-03 2004-10-14 Neurosearch A/S Derives de benzimidazole et leur utilisation pour moduler le complexe du recepteur gabaa
WO2007110374A1 (fr) * 2006-03-24 2007-10-04 Neurosearch A/S Dérivés de benzimidazole et utilisation de ceux-ci pour moduler le complexe récepteur gabaa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MIRZA, N. R. ET AL: "NS11394 [3'-[5-(1-hydroxy-1-methylethyl)benzoimidazol-1-yl]biphenyl-2- carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS , 327(3), 954-968 CODEN: JPETAB; ISSN: 0022-3565, 2008, XP002565109 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10624839B2 (en) 2014-03-13 2020-04-21 Neuroderm, Ltd. Dopa decarboxylase inhibitor compositions
US10813902B2 (en) 2014-03-13 2020-10-27 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11458115B2 (en) 2020-11-17 2022-10-04 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease

Similar Documents

Publication Publication Date Title
EP2319837B1 (fr) Dérivés de benzimidazole et leurs utilisations comme modulateurs du complexe du récepteur GABAa
US7858649B2 (en) Imidazole derivatives and their use for modulating the GABAA receptor complex
WO2010055133A1 (fr) Dérivés de benzimidazole et leur utilisation dans la modulation du complexe du récepteur gabaa
US7923464B2 (en) Benzimidazole derivatives and their use for modulating the GABAA receptor complex
US20060069135A1 (en) Benzimidazole derivatives and their use for modulating the gaba-a receptor complex
EP1877052A1 (fr) Derives du benzimidazole et leurs utilisations pour moduler le complexe du recepteur gabaa
EP2365971B1 (fr) Dérivés de benzimidazole et leur utilisation dans la modulation du complexe du recépteur gabaa
US20110257210A1 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US7335777B2 (en) Benzimidazole derivatives and their use for modulating the GABAA receptor complex
WO2010055127A1 (fr) Dérivés de benzimidazole et leur utilisation pour la modulation du complexe du récepteur gabaa
WO2010055126A1 (fr) Dérivés de benzimidazole et leur utilisation pour la modulation du complexe du récepteur gabaa
US7776900B2 (en) Benzimidazole derivatives and their use for modulating the GABAAreceptor complex
WO2010055125A1 (fr) Dérivés de benzimidazole et leur utilisation pour la modulation du complexe du récepteur gabaa
WO2010055131A1 (fr) Dérivés de benzimidazole et leur utilisation pour la modulation du complexe du récepteur gabaa
WO2010055130A1 (fr) Dérivés de benzimidazole et leur utilisation pour la modulation du complexe du récepteur gabaa
WO2010055129A1 (fr) Dérivés de benzimidazole et leur utilisation pour la modulation du complexe du récepteur gabaa
WO2010055124A1 (fr) Dérivés de benzimidazole et leur utilisation pour la modulation du complexe du récepteur gabaa
US20090062304A1 (en) Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex
EP1874735A1 (fr) Derives de benzimidazole et leur utilisation dans la modulation du complexe recepteur gabaa
EP1940801A2 (fr) Derives d'imidazole utilises pour moduler le complexe du recepteur gaba-a

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09751916

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09751916

Country of ref document: EP

Kind code of ref document: A1